Bimatoprost appears to be the most promising pharmaceutical agent in the area of hair loss study. It is already being used to treat glaucoma and inadequate eyelashes. The drug is well tolerable and extremely effective for both the conditions. Most of the users have found this solution as the best and easiest option for hair growth.
A new development for hair loss is currently being studied in clinical trials. The drug is bimatoprost, which has been previously used not only for treating glaucoma (a condition affecting the eye) but also for the lengthening of eyelashes. It is an FDA approved pharmaceutical agent to treat glaucoma. It has had tremendous success in an application for glaucoma. After its extended use, glaucoma patients began noticing the increased growth of eyelashes. Studies were concluded, and researchers approved it as a treatment of eyelashes. These results were promising, and manufacturers started selling it by thinking it could be lucrative for women seeking to grow stronger and thicker eyelashes. One of the most famous drugs for eyelash growth is careprost.
After the approval for eyelash growth, it was postulated that if bimatoprost could grow the lash strands thicker and longer then why not a hair on the scalp of people with hair loss. It comes to be a promising idea since it is a topically applied solution with minimal side effects. Many researchers studied Bimatoprost for a baldness cure. The positive results show that it is equally effective as a hair loss treatment.
Bimatoprost for hair loss- A study
The research found that Bimatoprost which mimics naturally derived compound called prostaglandins, significantly promotes hair growth on the scalp in people with mild hair loss. It appears to stimulate hair growth when applied topically to the scalp. The study shows significant differences in hair density associated with increased pigmentation and thickness. After 24 weeks, hair density found to be increased in the entire population who used the careprost solution on their scalp. The study revealed that the number of both anagen and telogen hair increased; it seems that bimatoprost recruits new hair into the anagen phase of the hair cycle. There is evidence of using Bimatoprost to treat androgenetic alopecia or common hair loss problem on the scalp. However, more research is required to determine the ideal dosage and duration of the treatment for scalp hair loss.
Researchers hope that this study will result in the development of a new therapy for hair loss, which should improve the overall quality of life of many people who suffer from balding.